Aurora kinase inhibitors in preclinical and clinical testing

Chun Hei Antonio Cheung, Mohane Selvaraj Coumar, Hsing Pang Hsieh, Jang Yang Chang

Research output: Contribution to journalReview article

83 Citations (Scopus)

Abstract

Background: Mitosis is a key step in the cell cycle governing the distribution of genetic material to the daughter cells. Any aberration in this process could lead to genomic instability. Aurora A, B and C, are members of the serine/threonine kinase family. Aurora kinases are essential for spindle assembly, centrosome maturation, chromosomal segregation and cytokinesis during mitosis. Abnormalities in the mitotic process through overexpression/ amplification of aurora kinase have been linked to genomic instability leading to tumorigenesis. Hence, use of aurora kinase small molecule inhibitors as potential molecular-targeted therapeutic intervention for cancer is being pursued by various researchers. Objective: To review the literature of aurora kinase inhibitors in clinical and preclinical testing. Method: Pubmed, Scifinder® and www.clinicaltrials.gov databases were used to search the literature for aurora kinase. Conclusion/results: Approximately 13 aurora kinase inhibitors are under Phase I/II evaluation at present for various cancers of different origins; and several others are in preclinical testing. Details of their preclinical/clinical results and important considerations for future aurora kinase inhibitor development are discussed. Considering the fact that aurora kinase plays an important role in the mitosis process and is involved in tumorigenesis, development of aurora kinase inhibitors for the treatment of cancer, either as a single agent or in combination with existing cancer treatment is warranted.

Original languageEnglish
Pages (from-to)379-398
Number of pages20
JournalExpert Opinion on Investigational Drugs
Volume18
Issue number4
DOIs
Publication statusPublished - 2009 Apr 1

Fingerprint

Aurora Kinases
Mitosis
Genomic Instability
Neoplasms
Carcinogenesis
Centrosome
Cytokinesis
Protein-Serine-Threonine Kinases
PubMed
Cell Cycle
Research Personnel
Databases

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{008fb6542fe8494c92b969b67892842c,
title = "Aurora kinase inhibitors in preclinical and clinical testing",
abstract = "Background: Mitosis is a key step in the cell cycle governing the distribution of genetic material to the daughter cells. Any aberration in this process could lead to genomic instability. Aurora A, B and C, are members of the serine/threonine kinase family. Aurora kinases are essential for spindle assembly, centrosome maturation, chromosomal segregation and cytokinesis during mitosis. Abnormalities in the mitotic process through overexpression/ amplification of aurora kinase have been linked to genomic instability leading to tumorigenesis. Hence, use of aurora kinase small molecule inhibitors as potential molecular-targeted therapeutic intervention for cancer is being pursued by various researchers. Objective: To review the literature of aurora kinase inhibitors in clinical and preclinical testing. Method: Pubmed, Scifinder{\circledR} and www.clinicaltrials.gov databases were used to search the literature for aurora kinase. Conclusion/results: Approximately 13 aurora kinase inhibitors are under Phase I/II evaluation at present for various cancers of different origins; and several others are in preclinical testing. Details of their preclinical/clinical results and important considerations for future aurora kinase inhibitor development are discussed. Considering the fact that aurora kinase plays an important role in the mitosis process and is involved in tumorigenesis, development of aurora kinase inhibitors for the treatment of cancer, either as a single agent or in combination with existing cancer treatment is warranted.",
author = "Cheung, {Chun Hei Antonio} and Coumar, {Mohane Selvaraj} and Hsieh, {Hsing Pang} and Chang, {Jang Yang}",
year = "2009",
month = "4",
day = "1",
doi = "10.1517/13543780902806392",
language = "English",
volume = "18",
pages = "379--398",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "4",

}

Aurora kinase inhibitors in preclinical and clinical testing. / Cheung, Chun Hei Antonio; Coumar, Mohane Selvaraj; Hsieh, Hsing Pang; Chang, Jang Yang.

In: Expert Opinion on Investigational Drugs, Vol. 18, No. 4, 01.04.2009, p. 379-398.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Aurora kinase inhibitors in preclinical and clinical testing

AU - Cheung, Chun Hei Antonio

AU - Coumar, Mohane Selvaraj

AU - Hsieh, Hsing Pang

AU - Chang, Jang Yang

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Background: Mitosis is a key step in the cell cycle governing the distribution of genetic material to the daughter cells. Any aberration in this process could lead to genomic instability. Aurora A, B and C, are members of the serine/threonine kinase family. Aurora kinases are essential for spindle assembly, centrosome maturation, chromosomal segregation and cytokinesis during mitosis. Abnormalities in the mitotic process through overexpression/ amplification of aurora kinase have been linked to genomic instability leading to tumorigenesis. Hence, use of aurora kinase small molecule inhibitors as potential molecular-targeted therapeutic intervention for cancer is being pursued by various researchers. Objective: To review the literature of aurora kinase inhibitors in clinical and preclinical testing. Method: Pubmed, Scifinder® and www.clinicaltrials.gov databases were used to search the literature for aurora kinase. Conclusion/results: Approximately 13 aurora kinase inhibitors are under Phase I/II evaluation at present for various cancers of different origins; and several others are in preclinical testing. Details of their preclinical/clinical results and important considerations for future aurora kinase inhibitor development are discussed. Considering the fact that aurora kinase plays an important role in the mitosis process and is involved in tumorigenesis, development of aurora kinase inhibitors for the treatment of cancer, either as a single agent or in combination with existing cancer treatment is warranted.

AB - Background: Mitosis is a key step in the cell cycle governing the distribution of genetic material to the daughter cells. Any aberration in this process could lead to genomic instability. Aurora A, B and C, are members of the serine/threonine kinase family. Aurora kinases are essential for spindle assembly, centrosome maturation, chromosomal segregation and cytokinesis during mitosis. Abnormalities in the mitotic process through overexpression/ amplification of aurora kinase have been linked to genomic instability leading to tumorigenesis. Hence, use of aurora kinase small molecule inhibitors as potential molecular-targeted therapeutic intervention for cancer is being pursued by various researchers. Objective: To review the literature of aurora kinase inhibitors in clinical and preclinical testing. Method: Pubmed, Scifinder® and www.clinicaltrials.gov databases were used to search the literature for aurora kinase. Conclusion/results: Approximately 13 aurora kinase inhibitors are under Phase I/II evaluation at present for various cancers of different origins; and several others are in preclinical testing. Details of their preclinical/clinical results and important considerations for future aurora kinase inhibitor development are discussed. Considering the fact that aurora kinase plays an important role in the mitosis process and is involved in tumorigenesis, development of aurora kinase inhibitors for the treatment of cancer, either as a single agent or in combination with existing cancer treatment is warranted.

UR - http://www.scopus.com/inward/record.url?scp=67649588612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649588612&partnerID=8YFLogxK

U2 - 10.1517/13543780902806392

DO - 10.1517/13543780902806392

M3 - Review article

C2 - 19335272

AN - SCOPUS:67649588612

VL - 18

SP - 379

EP - 398

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 4

ER -